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Proton therapy has become an increasingly more common method of radiation
therapy, with the dose sparing to distal tissue making it an appealing option, particularly
for treatment of brain tumors. This study sought to develop a head phantom for the
Radiological Physics Center (RPC), the first to be used for credentialing of institutions
wishing to participate in clinical trials involving brain tumor treatment of proton therapy.
It was hypothesized that a head phantom could be created for the evaluation of proton
therapy treatment procedures (treatment simulation, planning, and delivery) to assure
agreement between the measured dose and calculated dose within ±5%/3mm with a
reproducibility of ±3%. The relative stopping power (RSP) and Hounsfield Units (HU)
were measured for potential phantom materials and a human skull was cast in tissueequivalent Alderson material (RLSP 1.00, HU 16) with anatomical airways and a
cylindrical hole for imaging and dosimetry inserts drilled into the phantom material. Two
treatment plans, proton passive scattering and proton spot scanning, were created.
Thermoluminescent dosimeters (TLDs) and film were loaded into the phantom dosimetry
insert. Each treatment plan was delivered three separate times. Each treatment plan
passed our 5%/3mm criteria, with a reproducibility of ±3%. The hypothesis was accepted
and the phantom was found to be suitable for remote audits of proton therapy treatment
facilities.
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Chapter 1
1 Introduction and Background
1.1
1.1.1

Statement of Problem
General Problem Area
With about 2500 medical facilities treating over a million cancer patients with

radiation therapy modalities in the United States each year, there is a need to assure that
the treatment a patient gets in one area of the country is of the highest quality and not
significantly different than what one would expect to receive in another region (1).
Similarly, if institutions are participating in National Cancer Institute (NCI) funded
clinical trials involving radiation therapy trials, there needs to be some way of assuring
the specific Study Groups sponsoring the trials that each site is qualified and capable of
following the requirements of trial protocols. With over 1800 institutions participating in
more than 100 clinical trials involving radiation therapy, there are a significant number of
patients affected by the quality of radiation treatment. Treatment facilities are already
encouraged to carry out their own quality assurance (QA) programs, per
recommendations published by the International Commission on Radiation Units and
Measurements (ICRU) and contained in the American Association of Physics in
Medicine Task Group reports (AAPM TG reports), but there are currently very few
groups that assure excellence and consistency between independent radiation treatment
centers across North America.
The Radiological Physics Center (RPC), based at MD Anderson Cancer Center in
Houston, TX, is a QA group funded by the NCI who is charged with monitoring medical
institutions participating in clinical trials. The RPC was created with the goal of assuring
the NCI and cooperative clinical trial Study Groups that radiation dose delivered to trial
patients are “clinically comparable and consistent” (2). The RPC, unlike other QA groups
funded by the NCI who only monitor a fraction of the trial participants, monitors all
participating institutions (nearly 1850 sites) that participate in all cooperative group
clinical trials funded by the NCI. The RPC uses both onsite audit visits and remote
mailable dosimetric audit systems to assess the efficacy of each institution’s radiation
therapy procedures. The remote audit mailable program includes: (1) verification of an
1

institution’s machine output using thermoluminescent detectors (TLDs) or optically
stimulated luminescent detectors, (2) Verification of the patient treatment records sent to
the RPC for review and (3) Credentialing institutions through the use of the RPC’s
anthropomorphic QA phantoms that evaluate an institution’s ability to deliver a specific
treatment end to end, i.e. from imaging to planning to setup to dose delivery. The RPC
has numerous phantoms for photon therapies, including SRS head, head & neck, spine,
thoracic/lung, pelvic/prostate, and liver phantoms, but very few for proton therapy.
1.1.2

Specific Problem
Radiation Oncology therapy as given today is highly dependent on advances in

technology and computerization of treatments. One of the advanced technologies used to
treat patients is proton therapy. Although proton therapy has been around for some time,
recent advances in delivery techniques such as scanning beams and intensity modulated
proton therapy, have increased its popularity in the Radiation Oncology community,
particularly in the United States. According to the National Association for Proton
Therapy (3), there are currently nine proton centers treating patients, four more under
construction, and another 8-10 in the planning stages whereas only 5 years ago there were
only 3 centers treating patients. As proton therapy becomes more widely used to treat
certain types of patients, this form of therapy will be included as a radiation delivery
option in NCI funded clinical trials. As proton facilities look to enroll patients in clinical
trials, there is a need to evaluate each institution’s ability to provide accurate, precise and
consistent treatments.
The NCI wants the scientific integrity of its clinical trials to be flawless and as
such has funded several quality assurance groups to assist the Study Groups and to
monitor those institutions participating in clinical trials. One monitoring group, the
Quality Assurance Review Center (QARC), provides treatment record quality assurance
and data management for six NCI cooperative groups(4). Because of QARC’s
relationship with the Children’s Oncology Group (COG), it has been involved in
providing some proton therapy QA through the use of a questionnaire and proton therapy
benchmark case. The questionnaire allows QARC to assess the institution’s resources,
personnel and experience, while the benchmark case gives them confidence that the
2

institution can properly generate a treatment plan given guidance from a protocol (4).
While QARC and other monitoring bodies review records and monitor safety protocol
and violations, the RPC is the only group that oversees the quality of radiation therapy.
As such, the RPC is the quality assurance group best suited to develop a
credentialing process for the evaluation of proton therapy. Generally the RPC
credentialing procedure includes a site visit to the institution of interest where
measurements are taken using phantoms and dosimeters to assess the quality of radiation
therapy being delivered at the facility. With the introduction of proton therapy in clinical
trials, the RPC adapted two phantoms for the use in proton credentialing: a pelvis and
lung phantom (5, 6). The lung phantom had been modified with the use of balsa wood as
a lung-equivalent material, due to the similarities between balsa wood’s stopping power
and CT number in relation to the lungs’ correlating properties. The pelvic phantom was
similarly modified by changing the target and critical structure phantom materials to
more closely mimic corresponding anatomy based on stopping power and CT numbers.
The phantoms test the proton systems ability to deliver a conformal dose to a target, and
in the case of the pelvis phantom, avoid dose to surrounding critical structures. While
dosimetric methods and QA phantoms for testing radiation therapy facilities have adapted
to new developments in treatment modalities including proton therapy, the RPC does not
at this time have a mailable anthropomorphic head & neck phantom available to test
proton therapy treatment.
1.1.3

Importance of Topic
Quality control of radiation therapy is of utmost importance in assuring proper

treatment of patients as well as the safety of patients and personnel in the radiation
oncology field. However, the role of quality control has taken on new importance with
the lay press drawing increasing attention to radiation therapy incidents and medical
errors. A series of articles published in The New York Times in the Winter of 2010
exposed malpractice and radiation therapy errors, some of which led to serious
complications as well as fatalities of patients who had been mistreated (7, 8). From there,
the media has continued to draw attention to dangers of radiation oncology and there has
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been heightened skepticism of radiation therapy practices both by media sources and the
general public.
As delineated in one of the articles, new modalities are often accepted for use in
treating patients with little attention to how safety and quality assurance procedures may
have to be changed based on the newly employed advanced technology (7). Recognizing
that proton therapy requires distinctive QA procedures, the ICRU recommends quality
assurance checks for proton therapy that cover the treatment delivery system, patient
positioning and immobilization, and treatment planning (9). However, most centers using
proton therapy generally develop their own quality assurance practices specific to their
unique setup (e.g. different tests for passively scattered beams v. scanning beams, etc.)
following the basic principles laid out in the ICRU recommendations. Due to the variety
of QA programs and measurement techniques throughout the existing proton therapy
institutions, an independent evaluation of the accuracy of treatment delivery at each
center is needed if they are to participate in clinical trials. One technique to perform this
independent evaluation is through the use of one of the RPC’s anthropomorphic QA
phantoms built especially for proton therapy. Once the QA phantom is developed by the
RPC, it will be beneficial in ensuring nationwide treatment conformity, as well as
compliance of the radiation therapy centers participating in research protocols.
Quality assurance for proton therapy is just as, if not more, important as quality
assurance for other radiation therapy modalities. While the behavior of the proton Bragg
peak makes protons great for killing cancer cells, it also has a great potential to damage
healthy tissue if the range of the proton beam is miscalculated and regular tissue is
accidentally irradiated. Proton therapy, as mentioned in the introduction, has unique
requirements for quality assurance because different facilities have different machines
and equipment. In regards to beam calibration, it is recommended by the ICRU, and
required by the NCI for centers participating in cooperative group trials, that each proton
beam be calibrated according to TRS 398. This protocol walks each center through the
determination of the absorbed dose to water for the proton beam using a parallel plate or
cylindrical ion chamber, depending on the residual range (10).
Regular quality assurance procedures, however, have looser guidelines, as each
facility has set up their own method of checking the accuracy and precision of their
4

proton therapy treatment system. The ICRU has summarized some suggested quality
assurance procedures for both passive and scanning beam systems, as collected from sitespecific QA publications. These recommendations include daily checks of the beam
aperture alignment, room lasers, safety interlocks, patient communication systems and
patient positioning, depth dose and lateral beam profiles, monitor units and dose
monitors, and individual patient treatment setup, with additional checks required for
scanning beam systems, including dose rate, monitor ratios, beam position monitors,
depth dose curves in water, and calibration of the primary dose monitor (9). Weekly
checks include patient positioning and imaging modalities, beam-line apparatus, breath
cycle equipment, and verification of one patient dose in water (to be examined in three
dimensions for scanning beams) (9). Semi-annual, annual, or scheduled checks include
calibration of CT scanner Hounsfield units, x-ray alignment, tests of all therapy
equipment, and calibration of the primary dose monitor, and beam characteristics for
scanning beams (9). While most facilities follow these general practices, there is room for
variation as each center employs equipment developed by different manufacturers.
While it is not possible at this time to get every proton center to follow the exact
same quality assurance protocol, which might ensure consistency in performance across
centers, it is possible to review each center’s performance to ensure that their
individualized QA procedures are working. Beyond a uniform initial beam calibration,
the NCI has set forth additional guidelines for proton therapy centers looking to
participate in clinical trials. The NCI requires that these centers go through a
credentialing process with the RPC for the cooperative group running the trial. The
centers undergo a credentialing process through the RPC that includes several steps.
These steps include completion of a questionnaire, annual monitoring of the reference
proton beam outputs with the RPC’s TLD audit and dosimetry onsite visits that include
dosimetry measurements, review of QA procedures and a phantom irradiation. Part of the
RPC’s visit is to assure accuracy of the proton center’s Hounsfield to Stopping Power
conversion, treatment planning algorithm, and patient specific immobilization system
(11). There are a handful of other guidelines put forth by the NCI as well: a radiation
oncologist must be involved in the implementation of the clinical trial at each institution,
all doses must be expressed in terms of Cobalt Gray Equivalent (CGE) using an RBE of
5

1.1, and while GTV and CTV for treatment planning must be the same as it would for
photon protocol, the PTV created for each lesion should take into account site-specific
beam characteristics, such as lateral beam scattering and range uncertainties (11).

1.2 Hypothesis
With the current relevance and importance of proton therapy quality assurance,
this project is particularly timely. The hypothesis of this project is as follows: An
anthropomorphic head phantom can be created to evaluate proton therapy treatment
procedures (patient simulation, treatment planning, and treatment delivery) to assure
agreement between the measured dose and calculated dose within ±5%/3mm with a
reproducibility of ±3%. With this goal in mind, the specific aims of this project are:
1. Select a suitable head phantom design, evaluate tissue equivalent materials for

corresponding relevant patient anatomy and build the head phantom.
2. Image the head phantom, create two clinically relevant proton therapy treatment

plans using the passive scattered and spot scanning proton beams, and irradiate
the phantom multiple times with each treatment plan.
3. Measure the delivered dose distribution and the dose to specific points inside the

irradiated phantom.
4. Compare the measured and calculated point doses and 2D dose distributions to

determine deviations and precision.

1.3 Research Approach
In order to achieve the specific aims of the project, the following methodology
will be employed:
1. The stopping power and Hounsfield Units (HU) will be determined for the

phantom materials and compared to known stopping powers and Hounsfield Units
of corresponding human anatomy used for proton therapy.
2. The phantom will be imaged with MRI and this image will be fused with a CT

image set for target delineation and dose distribution calculations. Two treatment
plans will be designed using these images in the Eclipse proton planning system,
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according to the department’s standards for both the passive scattering and spot
scanning systems. The plans will be developed based on typical clinical
constraints used for designing treatment plans for brain cancer targets at the
Proton Therapy Center – Houston (PTC-H) and a radiation oncologist will review
and approve the final plans.
3. Radiochromic film and TLD capsules will be placed inside the phantom’s

cylindrical dosimetry insert and the phantom will be irradiated according to the
treatment plan. Each plan will be delivered a minimum of three separate times to
assess reproducibility of the phantom audit system.
4. The 2D dose distributions and absolute point doses determined from the film and

TLD will be compared with the calculated values of point doses, dose profiles and
planar dose distributions from the treatment planning system to determine the
agreement and reproducibility.

1.4 Limitations
There are two primary challenges in the development of a head phantom that can be
used to audit proton therapy for targets in the head. The first challenge is the creation of a
phantom that can be imaged appropriately. The latest Radiation Therapy Oncology Group
(RTOG) protocol, RTOG 0539, on the treatment of Meningioma requires that the head be
imaged using MRI for the purposes of lesion delineation, and then fused with a CT image
for dose calculation purposes (12). Anthropomorphic phantoms, however, are not usually
imaged with MRI since the solid materials that comprise the phantoms are not well
delineated with most MR imaging sequences. While it would be easy enough to mail out
this phantom with instructions to take a CT image instead of MR, it is desired that the
auditing process mirror typical treatment protocol and therefore the audit should
encompass the imaging component of the treatment delivery process. The second
challenge is determining what materials are to be used in the construction of the phantom
such that they are tissue equivalent based on proton interactions. The tissue substitute
materials used with photons do not necessarily meet the requirements to be substitute
materials for protons. Based on these two challenges, the difficulty comes in finding
phantom materials that are solid, tissue equivalent based on proton interactions, and show
7

up on an MRI. In addition, it is desired that the tumor be visible in the MR image, but not
easily distinguishable on a CT image.
The RTOG 0539 protocol also recommends head immobilization tactics such as
cast immobilization, modified stereotactic frame, or a camera-based localization setup
(12). These requirements are hard to meet due to the structure and solid nature of the
phantom, so special considerations have to be made for phantom immobilization. The
protocol also requires that weekly portal imaging be used for the initial treatment setup,
as well as periodically throughout the course of treatment (film or EPID). While the
periodic imaging cannot be integrated into phantom irradiations, the initial treatment
setup will utilize on-board imaging.

1.5 Literature Review
1.5.1

Proton Background
Proton therapy has long been of interest in the medical community due to the

behavior of protons in a medium. The existence of protons was suggested by Rutherford
in 1919 and the first particle accelerator was developed in 1930; 16 years later, it was
suggested that protons could be used for treatment of cancer (13, 14). What is exciting
about proton therapy is that protons, basic subatomic charged particles, follow the theory
of the continuous slowing down approximation, and the rate of energy loss of a proton
particle is found to be inversely proportional to the square of its velocity (15). As a
proton collides with other particles in a medium and experiences a decrease in velocity,
the energy loss is greatly increased causing a characteristic energy deposition known as
the Bragg peak. When beams of different energies are superimposed to create a spread
out Bragg peak (SOBP) in depth, the area of high energy deposition can be used to treat
a tumor of finite thickness as seen in Figure 1.1. In addition to the high dose region of an
SOBP, protons exhibit relatively low energy deposition on the proximal side of the peak,
and extremely low amounts of energy deposited on the distal side of the peak (13). This
is an advantage (in theory) of protons over more conventional therapeutic modalities such
as electrons, which have a higher relative entrance dose for both skin and proximal target
tissues, and photons, which exhibit a greater distal dose, as shown in Figure 1.1.
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Figure 1.1 Relative Depth-Dose curves of 6 MV photons, 20 MeV electrons, pristine
200 MeV protons, and a spread-out 200 MeV proton beam
The steep energy drop-off on the distal side of the proton SOBP means that the
dose prescribed to the lesion can deliver a highly conformal dose while sparing the
healthy tissue, or perhaps an organ at risk, especially that is located distal to the range of
the proton beam, indicating a possible advantage over photon therapy.
When a proton interacts with matter, it loses small portions of its energy due to
electromagnetic interactions with atomic electrons (15). The quantification of a proton’s
energy loss over a finite thickness of absorbing material is defined by the term mass
stopping power. The mass stopping power can be expressed as below (16):



 

²





²

²²²

²²

²

Equation 1.1
Equation 1.1 takes into

account the radius of the electron orbit (r), the rest energy of an electron (mc2), the atomic
number of the stopping material (Z), the charge of the proton (z), the ratio of the proton’s
velocity to the speed of light (β²), the atomic mass unit (u), the atomic mass of the
stopping material (A), and the stopping number (L(β)). The mass stopping power value
takes into account the mean excitation energy of atoms in the stopping material, the effect
of atomic shells, and the density-effect, or the effective reduction of stopping power due
to the proton’s projectile polarization (16).
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1.5.2

Biological Impact of Protons
In addition to the advantages that protons present due to their characteristic range,

protons are thought to have a greater biological impact than other therapeutic particles,
which can be more effective in causing damage in cancer cells. This higher biological
impact is caused by an increase in ionization along the path of the particle. Relative
biological effectiveness (RBE) is expressed as:
 
In 

 


 


Equation 1.2

Equation 1.2, Dose and Doseref are the doses

required to cause the same biological effect. The reference dose, Doseref, is based upon
either 60Co or 250 kVp photons (17). When using such a reference dose, an RBE of 1.1 is
generally accepted and used for protons (11, 18, 19). This means that protons themselves
have a higher RBE than conventional treatment with photons and electrons. In addition,
nuclear reactions with protons cause secondary particles (such as neutrons) that have
greater RBE, and can be more effective in killing the cells that make up cancerous lesions
(15).
When speaking of dose delivered by protons, the RBE is usually taken into
account and the dose is expressed in terms of Cobalt Gray Equivalent (CGE). The
equation for CGE for protons is listed in

  .   

!"

Equation 1.3 (20, 21):
  .   

!"

Equation 1.3

The above equation gives a value for dose, expressed in units of Gray (Gy), that is
comparable to photon or electron dose that have an RBE equal to 1.0. For uniformity and
clarity purposes, the NCI requires that radiation therapy groups participating in clinical
trials use CGE for dose information and prescription (11). It should be noted, however,
that many proton clinics are using the unit of GyRBE in reference to RBE dose.
1.5.3

Proton Therapy Beam Development
Protons used for therapy purposes are generally
The two most basic categories of proton
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1.5.3.1 Passive Scattering
When the accelerated protons reach the gantry,
The SOBP is created by beam range

Figure 1.2. Range Modulation Wheel (5)
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Figure 1.3. 160 (ID84) and 140 (ID85) MeV RMWs used at the PTC-H
The range of the protons can also be varied by inserting additional absorbers in the beam
path, as well as by changing the energy of the beam (18). At the PTC-H, range shifters
are introduced after the scatterers and RMW to shift the beam range in increments of 1
mm.
The passive scatter beam is also shaped by apertures and compensators (see Section
2.3.2.1 for images). The apertures are thick sheets of brass that are shaped according to
the outline of the target and placed on the outer edge of the treatment snout. These block
the protons outer transverse region of the lateral spread. Often two or three apertures are
used in treatment, depending on the energy of the beam used (higher energy beams
require a greater thickness of attenuator to block the field). The compensator is placed
immediately after the apertures. This allows proton beams to be molded to threedimensional objects, such as tumors. The compensator is usually made of acrylic and
shaped to the distal edge of the field using a computer-controlled raster drilling pattern.
1.5.3.2 Spot Scanning
For scanning proton beams, a pencil beam is
For the PTC-H’s spot scanning system, the
12

1.5.4

Dose Uncertainties

The range can be a source of uncertainty with proton beams. If the energy modulation is
not accurately implemented or achieved, the SOBP may deviate from what is expected.
This can result in underdosing the target or overdosing normal tissue.
There is also uncertainty introduced by the heterogeneity of the absorbing materials. The
manner in which the proton beam range is varied mirrors the way in which the range can
be changed in other absorbing materials, such as the human body. A section of high or
low density tissue can cause a shift in the range of protons if not properly accounted for
in treatment planning models. If the treatment planning system does not accurately model
the heterogeneities of the absorbing tissues, the dose delivered could be different from
what is predicted. This demonstrates the need for stringent quality assurance and
attention to detail on the part of the radiation therapy team.
1.5.5

Beam Monitoring
As the beam modulators cause variability in

1.5.6

Dose Distribution Measurements

In addition to monitoring the beam output, it is important to characterize the dose
distribution of the proton therapy systems to have an illustration of the behavior of the
beam for treatment planning and delivery purposes. As mentioned in the previous section,
ion chambers can be used to monitor the beam output at the treatment head as well as
depth dose profiles. 2D dose distributions can be captured using either radiochromic film
or 2D ion chamber arrays (24, 26). The measurements of 2D dose distribution are useful
in patient specific QA at proton therapy facilities.
1.5.7

Proton Therapy in Treatment of Brain Tumors
When developing the phantom, some thought
Meningiomas arise from the meninges, or
Proton therapy in particular is a good treatment
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2 Methodology
2.1 Phantom Design
2.1.1

Previous Phantom Designs

As part of the RPC’s role in remote monitoring of institutions that participate in clinical
trials, the center has created a number of mail-able dosimeter systems and phantoms. The
phantom program at the RPC has utilized a variety of creative scientific minds to create
heterogeneous phantoms for different regions of the body. There is an obvious advantage
to heterogeneous over homogeneous phantoms, as the body itself has a diverse
composition. More specifically, the RPC strives to create anthropomorphic
heterogeneous phantoms, which are not only varied in their composition, but mimic
anatomical composition. Some anthropomorphic phantoms, such as the one developed at
the RPC for the evaluation of Intensity-Modulated Radiation Therapy (IMRT), are
constructed with a tissue-equivalent surface and filled with water, while materials are
placed inside with tissue-equivalence to tumors and/or critical structures (31, 32). Water
is a good option for tissue-equivalent material, but it can be problematic. Air bubbles in
the water in the phantom can cause discrepancies in imaging, treatment simulation, and
dosimetry. In addition, water residue can cause mold to form in crevices of the phantom
material if not properly cleaned. This is particularly the case in a phantom that includes
real bones, such as a human skull.
The Alderson Average-Man phantom was created with a human skeleton cast in a
synthetic isocyanate rubber (33). The material of the phantom is tissue-equivalent and
durable, and can be cast around human bone as well as carved to represent anatomical
airways, making it a good option for a phantom to be sent to a customer or external
institution.
Phantoms designed by the RPC use various
2.1.2

The Anthropomorphic Head Phantom
Because there is still some uncertainty as to the
The phantom for this project was created with
Once the materials were measured and deemed
Axial CT images of the phantom were obtained
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Figure 2.1. Head phantom
A hole of 7 cm in diameter was drilled

Figure 2.2. Insert hole in phantom
The imaging insert was developed for the

15

a.
b.
Figure 2.3. MRI insert sketch (a.) and physical insert (b.), made of hollow acrylic
with nylon ball suspended from the superior surface
The CT/irradiation insert is designed as a high

16

Left
Post.

Figure 2.4. Dosimetry insert schematic of
This insert does not have a tumor embedded,
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Figure 2.5. Solid polyethylene dosimetry insert, with irradiated film and right TLD
capsule shown
Once the phantom is created, the next step is to
2.1.3

Determining Tissue Substitutes for Proton Therapy
To design the heterogeneous phantom, it was

The relative stopping powers of potential phantom materials were determined with the
passive scattering proton beams at the UT MD Anderson Proton Therapy Center of
Houston (PTC-H). The materials studied consisted of two different types of epolene, Mix
D plastic, a solid wax, and the solid material that makes up Alderson Rando phantom
material, all of which are supposedly water-equivalent materials (with respect to photon
therapy).
The PTC-H’s 3D PTW MP3 scanning water
At each measurement position, a four second
In order to determine the relative stopping
Once the data were recorded for both the water
To calculate the relative stopping power of each material, the depths of the distal
80% points were calculated using a linear slope formula between the two data points
straddling the distal 80% for both the water only and water plus slab depth dose curves. It
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is the preference of some to use the distal 90% points instead (35). However, it was
recommended that for the purposes of this experiment the distal 80% be used (36). As
long as the same two percent depth dose points are being compared, the relative stopping
power relationship will hold because only the shift in depth between the two depth dose
curves is being observed, and all points along the curve should shift by the same amount.
A linear regression was performed on the distal 80% points. Then, the relative stopping
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Equation 2.1 (37).
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Equation 2.1

A relative stopping power close to unity was desirable (meaning the material had
a stopping power close to that of water).
The phantom materials of interest were scanned with the Proton Center’s CT
machine, a GE LightSpeed RT16 (GE Healthcare, Waukesha, WI) to measure their
Hounsfield units. The materials were taped to the CT machine table which was aligned
with the lasers. An imaging technique of 120 kV and 300 mAs was used for the CT scans
of epolene and Mix D, while 120 kV and 350 mAs were used for “wax” and Alderson
material. The difference in technique was due to different technologists operating the
machines, but the small variation in mAs should not affect the CT number of the
materials, so the discrepancy was not a concern for the measurements. For both imaging
techniques, the scans were done in the fast helical setting with a pitch close to 1 and using
the head Scan Field of View. The CT numbers were obtained using the Eclipse treatment
planning system (Varian Medical Systems, Palo Alto, CA), taking the average of 10
measurements made across a central image of the material.
Once the RTOG 0539 protocol was reviewed, it was determined that to stay true
to common meningioma treatment procedures, the phantom needed to be imaged with
MRI for treatment planning. It was unclear initially whether or not the phantom material
would show up on an MR image due to its solid state. To determine whether or not this
was the case, an old anthropomorphic phantom from the RPC was imaged to see if any
parts were visible or distinguishable. A GE Signa HDxt 1.5 Tesla research scanner (GE
Healthcare, Waukesha, WI) at MD Anderson Cancer Center was used. The phantom was
placed in the supine position in an 8 channel array head coil. An initial localizer scout
was performed to see if any signal was detected. A fast spin echo was used due to the
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short time of T2* of solid materials. When a signal was detected, a second image was
obtained for an axial cross section of the mid-skull area. Surprisingly, a fairly detailed
image was obtained from this scan in which the outer shape of the phantom as well as
bony anatomy and air pockets inside were easily visible. An image with a greater scan
extent was then obtained using a more pertinent scan setting with a steady state free
precession acquisition, which for the GE machine was 3D Fiesta C. The contours of
bone, phantom material, and air were all still visible.
For MR images for treatment planning, RTOG 0359 recommends obtaining T1, T2,
FLAIR, and postcontrast multiplanar T1 images (12). The protocol says Gadolinium
contrast agent should be administered per institutional policy. Both of these
recommendations should be kept in mind for patient imaging, but were impractical for
phantom imaging, and as will be discussed further in Section 2.3.1.1, only one MR
sequence image set was used for the phantom simulation and treatment planning.

2.2 Developing the Phantom Components for Precise Setup
Patient setup was an important part of developing the phantom. For reproducibility
purposes, it was desired that the phantom have some kind of apparatus that would allow
for the precise setup of the phantom for imaging and treatment. Other phantoms at the
RPC have features such as an extended base at the neck or leveling screws that support
the head and neck phantom in a way such that it is positioned similar to a real patient’s
head and neck during treatment.
Per the recommendation of the PTC-H, the head & neck phantom was placed in the
supine position. The PTC-H treatment protocol also recommends using a Head & Neck
mask, head rest, and bite block, but it was determined that for ease of setup and
accessibility to the dosimetry insert during re-loading, these accessories would not be
employed. Instead, leveling screws were designed and incorporated into the base of the
phantom in the posterior, inferior region.

20

2.3 Testing the Phantom
2.3.1

Phantom Simulation

2.3.1.1 MRI Simulation
As with the phantom material scan, the MRI simulation for target delineation was
performed on a GE Signa HDxt 1.5 Tesla scanner. The MR phantom insert, containing
the nylon “tumor,” was carefully filled with tap water so as to minimize the number of air
bubbles. Once the insert was placed in the phantom, the phantom was placed in an eight
channel array head coil. The head was placed in the supine position, with the posterior
leveling screws extended for balance. Foam blocks were placed on each side of the head
to reduce vibration while the scan was being performed. The phantom was aligned such
that the localizing lights were aligned to the center of the head, using the medial
commissures of the eyes along the axial direction, and the center of the nose in the
sagittal direction.
A 3-plane localization was performed first to ensure proper setup. Several series
were acquired, but the 3D SPGR, GE’s version of an RF spoiled gradient echo, was used
for treatment planning purposes. This series matched the volumetric CT best for fusion,
and contained a well-delineated image of the target. An axial slice of the MR image set
demonstrates the target delineation in Figure 2.6:

Figure 2.6. 3D SPGR MR image at the center slice of the target
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2.3.1.2 CT Simulation
The CT images were acquired using the proton-dedicated GE LightSpeed RT16
scanner at the PTC-H. The dosimetry insert was loaded with TLD and film and placed
inside the phantom. The phantom was placed directly on the CT table in the supine
position. The posterior leveling screws were adjusted so that the head was supported in a
patient-like simulation fashion. Three pieces of tape were place on the head: one near
each of the left and right temples, and one in the center of the forehead. The laser lines
were marked on the tape, and small plastic bbs were placed at the vertex of each tape
line. A typical proton center head protocol was used for the CT simulation. An axial slice
of the target region of the CT images is shown in Figure 2.7, where the TLD capsules are
delineated.

Figure 2.7. CT image at the center slice of the target region
The images were transferred to the PTC-H’s Eclipse treatment planning system.
In Eclipse, the CT table was digitally replaced with the proton treatment couch. This was
done using an in-house DICOM digital couch replacement algorithm that runs through a
MATLAB application.
2.3.1.3 Image Fusion
The MR scan identifying the target and structures had to be fused with the CT
image to identify the target within the CT images to complete the treatment planning and
dose calculation process. For the image fusion, the Eclipse mutually shared algorithm
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was used. The region of interest was limited to the head. The algorithm’s registration uses
“manual tools” to translate the images for a generic match, then pixel registration for a
more detailed fusion guided by bony anatomy alignment. The “blend with” view can be
used to slide over the MR and CT images to see how closely the algorithm matched the
images.
2.3.2

Treatment Planning
Once an acceptable fusion was achieved, the target volume was contoured. The 2

cm diameter ball was designated as the GTV, and the PTV was created with a 0.5 cm
expansion in all directions, per RTOG 0539 specifications. Both passive scattering and
spot scanning proton beam plans were created. The dose prescription was 54 CGE, but
for the purposes of the project, the plans were created to deliver 5.4 CGE to the target
volume one time. This is a dose one-tenth the size of the prescribed dose was given to the
phantom target, per typical RPC protocol for head & neck phantoms (31). This lower
dose was chosen to accommodate the dose range of the Gafchromic film used in the
dosimetry insert. Per the RTOG 0539 specifications, all dose constraints were scaled to
10 percent of their original values. This meant that the 5.4 CGE must cover ≥ 95% of the
PTV, that the minimum dose to the PTV be at least 5.1 CGE, and that the maximum dose
to any point (≥ 0.03 cc) not exceed 6.2 CGE (12). Treatment plans were created using
both the passive scattering and spot scanning proton beams at the PTC-H. Digitally
Reconstructed Radiograph (DRR) images were also created in the treatment plans for
comparison with radiographs that were to be acquired before each treatment for
localization purposes.
2.3.2.1 Passive Scattering Plan
The passive scattering plan was designed using three beams: a posterior-anterior,
left vertex, and right vertex beam. The beams were equally weighted to deliver 5.4 Gy
(5.94 CGE) and combined to form a rough-edged uniform-dose sphere surrounding the
target volume. It is important to note that the passive scattering treatment plan was
initially designed with the intention of delivering 5.4 CGE to the target. However, when
the MU calculations were performed, the RBE was not accounted for and the dose
delivered to the phantom target was actually a physical 5.4 Gy.
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The isodose distributions are shown in Figure 2.8, and the beam parameters are
listed below in Table 2.1.

a.
b.
Figure 2.8. Passive Scattering treatment plan shown in the coronal (a) and sagittal
(b) planes
Passive Scattering Treatment Plan
Prescribed Dose: 540 cGy
Beam
A
B
PosteriorLeft
Beam Name
Anterior
Vertex
Beam Energy [MeV]
160
140
Gantry Angle
180º
75º
Couch Angle
0º
320º
Snout Position [cm]
30
25
Dose to isocenter [cGy]
181.9
181.3

C
Right
Vertex
140
285º
40º
25
182.2

Table 2.1. Passive Scattering treatment plan parameters
For each field, two brass apertures (Figure 2.9) and one compensator (Figure
2.10) were created at the in-house PTC-H machine shop and checked against the
treatment plan specifications.
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Figure 2.9. Passive Scattering beam aperture

Figure 2.10. Passive Scattering beam compensators for (from left to right) beams A,
C, and B
The phantom was irradiated on the G1 passive scatter gantry at the PTC-H. The
treatment plan for the phantom had been created for the G2 gantry, so despite the beams
being matched (within one percent), the Digital Imaging and Communications in
Medicine (DICOM) commands had to be converted to the right syntax for the G1 gantry.
This was accomplished by using a DICOM editor and changing the beam modulation ID
from 84 to 20 for the 160 MeV beam, and from 85 to 21 for the 140 MeV beam, as well
as a few other beam identifiers.
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The monitor units (MU) were calculated for each field based on
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Equation 2.2

The relative output factor, range
Passive Scatter Treatment Plan
Prescribed Dose: 540 cGy
Beam
A
B
C
Dose to isocenter [cGy]
181.9 181.3 182.2
Relative Output Factor
0.865 0.927 0.927
Range Shifter Factor
0.967 0.981 0.996
SOBP Factor
1.295 1.073 1.073
MU Delivered
167.4 185.3 182.0
Table 2.2. Monitor Unit (MU) parameters for the passive scattering treatment fields
2.3.2.2 Spot Scanning Plan
The spot scanning plan was designed using the

a.
b.
Figure 2.11. Spot scanning treatment plan shown in the coronal (a) and sagittal (b)
planes
The beam parameters are listed below in

Beam

Spot Scanning Treatment Plan
Prescribed Dose: 540 CcGyE
A
B
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Beam Name
Nominal Beam
Nominal SOBP
Gantry Angle
Couch Angle
Snout Position
Dose [CcGyE]
MU

Left
108
3.2
90º
315º
38
270
63.6

Right
113.4
3.37
270º
45º
38
270
62.5

Table 2.3:
Spot Scanning Treatment Plan
Prescribed Dose: 540 CcGyE
Beam
A
Beam Name
Left Vertex
Nominal Beam Energy [MeV] 108
Nominal SOBP Width [cm]
3.2
Gantry Angle
90º
Couch Angle
315º
Snout Position [cm]
38
Dose [CcGyE]
270
MU
63.6
Table 2.3. Spot scanning treatment plan parameters

B
Right Vertex
113.4
3.37
270º
45º
38
270
62.5

The phantom was irradiated on the G3 spot scanning beam at the PTC-H on. The monitor
units for this plan are calculated by the Eclipse treatment planning system, so a manual
MU calculation was not required for this plan, as was the case for the passive scattering
plan.
2.3.3

Treatment Delivery

2.3.3.1 Passive Scattering Irradiations
The phantom was set up in the supine
Orientation Nozzle Cage
kVp
65
65
mA
630
500
ms
80
60
Table 2.4. kV imaging parameters for PTC-H proton treatment setup
The x-ray images were compared to DRRs
The first passive scattering irradiation trial
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Once the first trial irradiation was delivered,
Once the phantom was reloaded with unirradiated dosimeters, it was repositioned on the
treatment couch using the lasers to align with the new tape markings. For the second
irradiation trial, the leveling screws at the base of the phantom were adjusted so the tape
markings aligned with the lasers, as it was determined that the screws had been bumped
during reloading. Another set of x-rays was acquired to verify the positioning of the
phantom. No adjustments were made to the phantom or the couch. The film and TLD
were reloaded again for the third trial irradiation, and the fields were verified with x-ray
images.
2.3.3.2 Spot Scanning Irradiations
For irradiation, the dosimetry insert was
The treatment plan had been designed to deliver 54 CGE over the course of 10 fractions,
so only the first fraction was delivered for each trial, for a dose of 5.4 CGE. The first spot
scanning irradiation trial was irradiated according to the treatment plan, with the left
vertex beam, beam A, delivered first. Beam A had a gantry angle of 90º, a couch angle of
315º and a nominal beam energy of 108 MeV. Beam B, the right vertex, was delivered
next, with a gantry angle of 270º, a couch angle of 45º, and nominal beam energy of
113.4 MeV, which is the energy of the proton spots with the distal 90% range at the
deepest layer.
Once Trial 1 irradiation was delivered, the phantom was removed from the couch and
reloaded with TLD and film. Again, x-ray imaging was used to assess phantom alignment
before the doses were delivered and calculate necessary couch shifts. The same procedure
was followed for the third trial as well.
2.3.4

TLD

2.3.4.1 Absolute Dose Determination
The RPC has developed a mailable TLD
Thermoluminescent dosimeters were used to measure
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Equation 2.3 will be used:
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Equation 2.3

The dose measured from TLD is calculated
The sensitivity correction factor is perhaps the most important as it can vary
between individual readout sessions due to factors such as system electronics and the
reader planchette (41). The correction factor looks at the system sensitivity (dose per
reading) of a specific batch of TLD. S is usually calculated by irradiating TLD to a
known dose (using an ion chamber measurement for reference) and reading out these
TLD both before and after the TLD reading session. This factor can be measured by
dividing the known dose by the TLD response for those measurements (T’) and

("4"2′ ×′×1′

Equation 2.4:
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Equation 2.4

where L’ and T’ are the relative linearity and fading factors of the TLD powder batch.
The energy correction factor takes into account that TLD crystals have a small
energy dependence. The factor is found by comparing the output per dose of a TLD at a
60

Co energy (reference energy) to the energy of a proton beam. This TLD proton energy

correction factor was determined to be the same for all proton energies tested by the RPC
and is unity.
The linearity correction factor accounts for the slight non-linearity of TLD
response over a wide range of doses. To find this correction factor, several TLD were
irradiated over a range of doses. For low doses, there is a linear adjustment that needs to
be made, but at higher doses, the relationship becomes logarithmic. In the dose range we
used, the linearity correction factor is found with inverse of response of the TLD
response v. dose curve, as described in the following =&
&  + 7
Equation 2.5:
  &   + 7

Equation 2.5

where a and b are coefficients specific to each batch of TLD.
The fading correction factor takes into account the recombination of some
electron-hole pairs before the TLD dosimeter is read out. The RPC uses a double
exponential fading correction factor based on a plot of time v. percent of signal obtained
in readout:
1

.88
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Equation 2.6

The change in the fading correction is minimized by waiting a minimum of 14
days after irradiation to read out the dosimeters. The RPC uses the same fading curve for
all batches of TLD as there is little variation in this correction factor when the minimum
readout time is standardized.
The TLD in the phantom for each irradiation consisted of two double-loaded LiF
TLD-100 dosimeters (Quantaflux, LLC, Dayton, OH). Each capsule was placed 3 mm off
axis, one above and one below the center line.
2.3.4.2 TLD Characterization
The TLD batch used for the project was named batch B07 and had been
characterized by the RPC prior to irradiation. As discussed in the previous section,
correction factors are needed for calculation of TLD dose. For the linearity correction
factor for the batch of TLD used the slope (m) and y-intercept (b) found in =&
&  +
7

Equation 2.5 are -0.00027842 and 1.08353, respectively. For the

fading correction factor, the 1 

.88

Equation 2.6 parameters are

9:! ; 9.!

listed in Table 2.5.
N
1.3493
a
1.2815
b
0.00010885
c
0.06781
d
0.071908
x
Days between irradiation and reading
Table 2.5. TLD fading correction factor constants

2.3.4.3 TLD Evaluation
The TLDs were read out after 21-23 days, so as to minimize the effects of fading.
The TLD was read in between a series of standard and control TLD which had been
irradiated using the ADCL’s 60Co machine. An unexposed TLD-100 pack was used as the
background, and its reading was subtracted out from the readings of the exposed TLD.
 

2

× × × ×1

Equation 2.3 was then used to calculate the

dose delivered to each TLD. TLD have been found in some cases to underestimate proton
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dose by about 7%, but this is mostly due to positioning errors (38). In a previous study
done by the RPC for the development of a head & neck phantom, TLD dosimeters were
found to have an accuracy of ± 4% and precision of ± 3% at a 90 % confidence interval
(31).
For this experiment, a ratio between calculated TLD dose (based on the treatment
planning model) and measured TLD dose would be deemed acceptable within the range
of 0.95-1.05 in order to meet the 5% point dose agreement criterion. The coefficient of
variation was used to calculate reproducibility, and COV values of less than 3% were
considered passable.
In order to test statistical significance of the TLD results, a one-sample t-test was
performed with a significance level of 0.05. The t-test values was computed using the
equation below (42):
!
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Equation 2.7

where x̄ is the mean ratio of calculated v. measured TLD dose, CD is the null hypothesis,
which we define to be 0.949 (outside of the 5% limit, where s is the standard deviation
and n is the sample size, three trials. The critical value was found using the TDIST
function, which yields the probability for a t-test distribution. The statistical significance
was found by finding the p-value, which if less than 0.05 was said to be statistically
significant. If the p-value was greater than 0.05, the data would be considered not
statistically significant, and the hypothesis would be rejected.
2.3.5

Film

Another passive dosimeter that can be used effectively in a mailable monitoring program
is radiochromic film. The RPC already uses this film as part of its mailable dosimetry
program. Radiochromic film is a good option for finding the dose distribution of a
radiation beam, as it exhibits no angular dependence, a high spatial resolution, and a low
spectral sensitivity (31). Another advantage of radiochromic film is that it is tissueequivalent, so as a beam passes through it, the behavior of the particles shouldn’t be
disrupted (43).
Gafchromic® EBT2 is yellow in color and uses a
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Polyester Overlaminate (50 µm)
Adhesive (25 µm)
Topcoat (5 µm)
Active Layer (20 µm)
Polyester Substrate (175 µm)
Figure 2.12 Design of Gafchromic® EBT2 film showing the various layers of the
film
One advantage of EBT2 film over
In order to assure accuracy of the film measurements, the film was calibrated with
a passive scatter beam at the PTC-H. Six doses were chosen for irradiation: 50, 150, 250,
350, 550, and 750 CcGE. These doses were chosen because they are the standard doses
delivered for photon beam calibrations at the RPC. The MU necessary to reach each dose
" ./ 01&". $%! 1& ! 0# 01
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Equation 2.8:
Equation 2.8

The measurements were taken in a water tank. A range shifter was not used for
these measurements, so the range shifter factor in this case was 1. An SOBP of 5 cm was
used, and the film was placed in the middle of the SOBP, perpendicular to the beam. An
ion chamber was placed in the field for reference. The six dose measurements were
collected for beam energies of both 140 MeV and 160 MeV, the energies of the passive
scatter treatment beams.
The films were scanned using the red light CCD Microdensitometer for
Radiochromic Film Model CCD100 (Photoelectron Corporation, Lexington, MA) at the
RPC. A flat field adjustment was made using a blank piece of film from the same batch.
The average optical densities were obtained for each dose using ImageJ software
(Rasband 1997-2011), and a calibration curve was created with a third degree polynomial
fit.
It was determined that creating a proper dose response curve for the spot scanning
system was beyond the scope of this project. Other studies, such as one performed by
Zhao et al., have found the OD-dose calibration curve of spot scanning systems similar to
that of scattered beams (46). As such, it was decided that a measurement of a uniform
field of a known dose with the spot scanning system could be compared to the passive
scattering dose response curves, and if that dose was within 5% of what was predicted by
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the polynomial fit, the passive scattering dose response curve would be used. A uniform
10x10 cm2 spot scanning beam with an SOBP of 10 cm was delivered to a piece of film
from the same batch. The OD-dependent dose measured was compared to the dose
delivered.
Film was placed in the coronal and sagittal planes of the dosimetry insert in order
to observe the dose distribution of the proton treatment. The film was all cut using the
same template, and each coronal piece was cut in half to allow the sagittal piece to
intersect it in the middle of the target location.
EBT2 film should always be scanned in the same direction and with the same
orientation. To ensure this process, the pieces of film were marked with permanent
marker in the outer corners, indicating orientation. It was recommended by International
Specialty Products, the manufacturer of this film, that the film rest for at least 24 hours
before being read out to ensure dose accuracy (44). The films used in the phantom
irradiations were read out after two days.
2.3.6

Film, TLD, & CT Registration
The film and TLD needed to be registered with the CT images for analysis

between the treatment plan dose clouds and dose delivered. The RPC uses in-house
developed software called rpcfilm that registers CT images and the dose distribution with
TLD and film locations and the corresponding measured dose distributions.
Pin pricks on the film provide spatial orientation and convenient registration
points for the program. It is necessary to set a central axis and measure the distance
between the pin pricks and that origin. This was done using the isocenter of the target as
the origin. Pricked pieces of film were placed on grid paper for alignment and the
coordinates of the pin pricks were measured using calipers. These coordinates were
entered into the excel file under the corresponding “sagittal” and “coronal” labels. The
CT images were registered to the system by setting the center of the target as isocenter
and measuring the distance to four pins in the dosimetry insert.
Once the irradiated film has been scanned into the system and is pulled up in
rpcfilm program, the pin-pricks can be identified and the spatial orientation of the film is
registered on one coordinate system, as delineated in Figure 2.13. The CT image set is
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opened with Computational Environment for Radiotherapy Research (CERR) software
and pins are used to mark the spatial coordinates and register the images to a second
coordinate system. The program then uses the program CERR to register both the film
and the CT image set to a third set of coordinates so that the two can be compared.

Figure 2.13. Pin pricks from coronal film picked for registration with pre-measured
points
When the registration occurs for both the film and the treatment plan image
coordinate systems, error in the form of root mean square (RMS) is calculated by the
rpcfilm program to assess the goodness of fit. The upper limit on the RMS for our point
registration was set at 1mm so as to minimize propagation of error. These errors are
recorded as “RMS Error” for film registration and “RMS 3D” for CT image registration,
as shown in Figure 2.14.
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Figure 2.14. The RMS errors for film and CT registration, as displayed in
MATLAB
When the film is properly registered, a dose response calibration curve is applied
to convert the optical density of the film to dose. The TLD positions are also recorded
based on the center of the active portion of the capsules in relation to the film coordinate
system. The dose grid of the film is scaled using the TLD dose, which is applied to the
points on the film where the TLD capsules have been assigned. The doses for the rest of
the film profile adjust accordingly.
2.3.7

2D Gamma Analysis
The agreement between 2D dose distributions was evaluated using a gamma

analysis procedure, with dose or distance agreement criteria of both ±5%/3mm and
±5%/5mm. The comparison analysis can be performed once the CT data and film had
been registered. A data omission mask was applied to regions of the film that we did not
want included, such as the pin pricks, pen marks, and the strip between the two pieces of
coronal film, as seen below in Figure 2.15. The RPC uses a pixel pass rate of 85% for
gamma analysis, so the same criterion was used for this project.

Figure 2.15. Masks applied to the coronal film to avoid comparison between
compromised areas
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2.3.8

Distance to Agreement Measurements
With the dose profiles created by the gamma analysis in the rpcfilm program,

distance to agreement (DTA) measurements could be calculated between the treatment
planning system and the delivered dose profiles. These measurements were calculated in
the regions of steep dose fall-off beyond the target. This is done by fitting a regression
line to the dose fall-off regions, starting at the 80% dose point and extending to down as
far as the 30% dose point. The distance in millimeters is then measured between where
these dose points fall in the planned dose distribution and on the film. An average
displacement for each side of the target is then calculated (i.e. +/- mm shift left/right,
superior/inferior, anterior/posterior). With our gamma analysis acceptance criteria of
±5%/3mm, it is desired that the DTA measurements are less than 3 mm, and less than 5
mm for the loser ±5%/5mm criteria. While the gamma analysis tells us the percentage of
pixels that pass the criteria, the DTA measurement quantifies the average shift between
treatment planning dose and delivered dose.
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3 Results
3.1 Phantom Materials
3.1.1

MR Insert Materials
For the MR phantom insert, the relative stopping power and CT numbers were

irrelevant to the selection of the materials, as this insert will not be irradiated with the
proton beam, nor imaged with CT. Acrylic was chosen for the shell of the MR insert and
the cylinder was left hollow to be filled with water. The target was made of a nylon
sphere with a diameter of 2 cm, as discussed and shown in Section 2.1.2.
3.1.2

Material Stopping Powers and HU
Recalling that the purpose of the first specific aim was to find materials with

relative stopping powers (RSP) and CT numbers close to those available in the treatment
planning system calibration curve for tissue substitute materials, several tested materials
will be discussed in this section. The complete results of the relative stopping power and
HU measurements are shown below in Table 3.1.
Materials
Relative Stopping Power CT Number [HU]
Alderson Material
1.00
16 ± 5
Epolene
0.95
-122 ± 2
Mix D
-11 ± 40
Wax
1.04
7±4
Table 3.1. RSP and CT Number of materials tested for the phantom
Epolene was found to have a promising relative stopping power as compared to
water. However, the Hounsfield units for epolene were not close enough to water to allow
for its use as a tissue equivalent material (-122 ± 2 HU). Another material, Mix D, had
highly variable HU (range: -52 – 123 HU) due to the heterogeneity of the mix itself. As
the material was not available in a more homogeneous form, it was determined ineligible
as a tissue-equivalent material and thus not scanned with the proton beam. A waxy
material was tested, and while its average HU was close to that of water (7 ± 4), the
relative stopping power was not the closest to water of all the materials tested. The
Alderson material was tested and found to have a relative stopping power and HU close
to water, with a relative stopping power of 1.00 and a mean HU of 16 ±5. The proton
depth dose curves measured in water with and without the Alderson material in the
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beam’s path that were used to determine the relative stopping power of the Alderson
material are seen in Figure 3.1:

Relative Depth Dose [%]
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Figure 3.1. Depth dose curves of water and water with Alderson material present
Due to the water-like properties of the Alderson material, it was deemed
acceptable as a water and soft tissue substitute for the phantom. Based on stopping power
measurements taken previously by the RPC, high density polyethylene was chosen for
the dosimetry insert. For the purpose of comparison to the treatment planning system, the
RSP and HU of each material is graphed along with the PTC-H Eclipse treatment
planning system calibration curve in Figure 3.2 (5, 35).
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Figure 3.2. HU v. RSP of materials tested compared to PTC-H Eclipse treatment
planning system calibration curve
The absolute error of the material thicknesses was 0.002 mm for each
measurement, so the total error of the material thickness calculations was 0.004 mm. The
depth dose scanning system is believed to be accurate within 0.1 mm. This gives a total
error for the Relative Stopping Power of about 0.5%.

3.2 Film Calibration
The film calibration irradiations yielded dose response curves using passive
scattering beams. The two dose response curves for 140 MeV and 160 MeV proton
beams were compared and found to be essentially identical, as shown in Figure 3.3.
Because of the similarity between the two curves, the 140 MeV curve fit was used for all
data analysis. This curve was chosen because two of the three passive scattering beams
used to irradiate the phantom were 140 MeV. The 160 MeV curve was only 1.5%
different from the 140 MeV fit, while the “average” polynomial fit provided a 2.1%
difference from the 140 MeV fit, so it was determined that the 140 MeV fit would be
acceptable for all data, as it most closely represented the weighting of energies. The
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greatest standard deviation of the optical density measurements was 0.014, and the COV
centered around 1.0%. The equation used for film calibration in the CERR file is shown
in Figure 3.3:
  LM. LM08 N . 8O0L + P. Q0

Equation 3.1

Comparison of Film Calibration Curves
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Figure 3.3. Gafchromic® film proton dose response calibration curves for 140 & 160
MeV passive scattering beams
For assessment of the appropriateness of the passive scattering dose-response curve
for the spot scanning system, the optical density of a uniform field of irradiated film was
measured. The calculated dose based on the passive scattering calibration curve was
within 5% of the measured delivered dose, which was determined to be close enough to
allow for the use of the 140 MeV polynomial fit for the spot scanning films as well. The
actual dose determined by the film using the calibration curve is scaled by the TLD point
doses. Thus, as long as our calibration curve can provide a dose from film that is close to
the expected value, the absolute dose can be determined in conjunction with the TLD
measurements.
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3.3 Passive Scattering Phantom Dose Measurements
3.3.1

Absolute Dose Comparison
The phantom doses from each passive scattering irradiation trial were measured

with TLD and compared to the calculated doses from the Eclipse treatment planning
system. The right anterior TLD was expected to receive a physical dose of 540 cGy and
the left posterior TLD was expected to receive 545 cGy. The values for the calculated
and measured doses, as well as the ratio of the measured to calculated doses, are given in
Table 3.2:

Trial 1

Trial 2

Trial 3

TLD
Location
Right
Anterior
Left
Posterior
Right
Anterior
Left
Posterior
Right
Anterior
Left
Posterior

Passive Scatter
Calculated Dose [cGy] Measured Dose [cGy]
- TPS
- TLD

Meas./Calc. Dose

540

520.9

0.965

545

527.8

0.968

540

527.8

0.977

545

535.2

0.982

540

528.2

0.978

545
534.2
0.980
Table 3.2. Point dose comparisons between the treatment planning system and TLD
for passive scattering
All of the TLD measured doses were less than calculated for both positions in
each irradiation trial, ranging from 1.8% - 3.5%. Our TLD results are found to be within
±4% of calculated values. This is within our acceptable criteria of 5% tolerance for dose
agreement.
The reproducibility of the phantom measurements was computed by calculating
the coefficient of variance (COV) between point measurements in the target. This was
done using the average measured doses from the three trials for each TLD location and
can be seen in Table 3.3.
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Passive Scattering Doses
Right
Left
TLD Location
Anterior
Posterior
Calculated Dose [cGy]
540
545
Measured Dose Avg. [cGy]
525.6
532.4
COV
0.78%
0.75%
Measured/Calculated Dose
0.973
0.977
Table 3.3. Average of measured TLD doses from passive scattering beams for three
trials
The COVs for each TLD location both measure less than 0.8%, well under our
3% reproducibility criteria. The small disparity between trial measurements show that we
were able to set up the phantom in a reproducible fashion and that it meets the RPC
phantom irradiation standard. These results are comparable to those mentioned in Section
2.3.4.3, as found in the phantom study by Molineu et al., where photon phantom
measurements were found to have 4% accuracy between various institutions. With such a
small coefficient of variation, it may be that the lower TLD measured doses were caused
by a systematic error due to a shift in the phantom positioning that may have been caused
by a loose leveling screw that could have moved one or both of the TLD into a lower
dose region. This type of small positioning error would have been hard to detect with on
board imaging.
3.3.2

2D Dose Distribution Analysis
The two-dimensional dose distributions were analyzed by comparing the

treatment planning dose clouds to the reconstructed dose profiles obtained from the
phantom films in the coronal and sagittal planes. The film and CT registrations were
achieved with an RMS < 1 mm for all trials, with the RMS Error ranging from 0.130.8672 mm for the film, and an RMS 3D ranging from 0.75-0.9 mm for the CT images. A
2D analysis was performed on the data, using the pass criteria of ±5%/3mm and
±5%/5mm. The gamma analyses for passive scattering trial 1 in the sagittal plane are
shown below in Figure 3.4.
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a.

b.
Figure 3.4. Passive scattering trial 1 sagittal gamma analysis (a. 5%/3mm, b.
5%/5mm)
The complete gamma analysis results for the passive scattering plan are listed in

Table 3.4.
Passive Scattering
2D Gamma Percentage of Pixels Passing
5%, 3mm 5%, 5mm
91.50
98.74
Trial 1 Coronal
Sagittal
93.90
94.69
91.28
97.63
Trial 2 Coronal
Sagittal
91.85
98.62
88.00
96.26
Trial 3 Coronal
Sagittal
94.86
98.61
Table 3.4. The gamma analysis pass rates for the passive scattering irradiations
Using the pixel pass rate of 85% that the RPC uses, each trial passed both the
5%/5mm and the stricter 5%/3mm gamma analyses. With the range uncertainties
associated with proton irradiations, we expect to see some shifts in dosimetric dose
profiles when compared with treatment planning dose clouds. As expected, the pass rates
were greater for the 5%/5mm criteria, as it allows for a greater distance disagreement in
pixel shifts. Overall, the sagittal films showed better pass rates than the coronal films.
This is not too surprising, as two separate pieces of film were used in the coronal plane,
while one solid piece was used in the sagittal plane. The left and right coronal films were
not consistently cut from the same region of the EBT2 film, which may have caused
some variability in dose response due to the slight variations in film composition over the

43

profile of the film. If the experiment were to be repeated, it would be done so with the
coronal films cut from adjacent regions of the larger sheets of film.
Despite shortcomings of the experimental design, the pass results of the gamma
analysis are in agreement with other studies that verify dosimetry with measurements,
such as a patient-specific QA study by Arjomandy et al. that yielded similarly high pass
percentages (47).
3.3.3

Distance to Agreement
For the passive scattering trial irradiations, the distance to agreement (DTA)

values were measured between the treatment planning system and the dose profiles
collected from the scanned films. The average distance to agreement from the three
irradiation trials are listed in Table 3.5. Often, DTAs are presented in overall shifts in a
particular plane, such as 0.5 mm superior. However, as evident in Table 3.5 for the S-I
and A-P directions, the shifts did not all occur in a unilateral direction, and the shifts in
the L-R directions were much greater on the right side than the left.

Left
Right
Inferior
Superior
Posterior
Anterior

Passive Scattering
Distance to Agreement Shifts
Average DTA [mm] Std Deviation [mm]
0.6
0.6
3.7
0.4
-1.1
0.6
0.6
0.7
-0.8
0.5
0.8
0.8

Table 3.5. Distance to agreement measurements between the dose distribution from
treatment planning system and from film measured for passive scattering proton
beams
For these calculations, a regression fit was calculated for the falloff regions of
both the planning system and film profiles. Due to the relatively small size of the film
pieces, the regression lines were calculated over varying ranges of the dose falloffs,
always starting at the 80% dose point, but ending anywhere from the 65% dose point to
the 30% point. The values for each profile were kept consistent for all film trials. The
right-left profile of the coronal films is shown in Figure 3.5 with corresponding distance
to agreement measurements.
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Figure 3.5. Passive scattering trial 1 right-left dose profile DTAs, measured in the
coronal plane
As shown above in the L-R direction, there was a much greater shift observed on
the right side of the profile than the left side. This calculation is confirmed by the gamma
analysis in the coronal plane, where we see more pixels failing the 3mm criteria on the
right side of the film than the 5mm criteria, as shown in Figure 3.6.
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a.

b.
Figure 3.6. Passive scattering trial 1 coronal gamma analysis (a. 5%/3mm, b.
5%/5mm) with areas of greatest disagreement circled
One set of coronal films was rescanned with adjusted alignment, but this

realignment did not produce any improvement in the distance to agreement or pixel pass
rates of the trial, which suggest the error in agreement originates in the actual amount of
radiation dose delivered. However the error also could have derived from an
inconsistency in the physical composition of the two adjacent pieces of film, or poor
spatial registration of the film marks.
This was not the case in the S-I shifts – as there was a relatively uniform
contraction inward from the treatment plan dose profiles to the film, as delineated in
Figure 3.7. The DTA measurements were taken from the 80% to 30% dose points on the
inferior side, and the 80% to 65% dose points on the superior side.
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Superior-Inferior Profile - Coronal Plane
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Figure 3.7. Passive scattering trail 1 S-I dose profile DTAs, measured in the coronal
plane
As shown above, the S-I DTAs do not suggest an overall shift of the phantom, but
rather that the dose delivered does not reach the full S-I extent that the treatment plan
predicts. The shifts are small, however, and well within the acceptable tolerance limits of
3mm. In Figure 3.7 it may also be the case that we observe the underresponse of film in
the distal edges, which would agree with previous studies that show a film underresponse
in the distal edge of the SOBP that may be attributable to an LET dependence of the film
that results in higher recombination in the distal edge that prevents the film from
polymerizing (43, 46, 48).
In the A-P direction, we saw similar DTA trends as the S-I profiles. Results from
Trial 1 are shown in Figure 3.8. The DTAs were calculated using the 80% to 65% dose
points on the posterior side, and the 80% to 40% dose points on the anterior side.
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Anterior-Posterior Profile - Sagittal Plane
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Figure 3.8. Passive scattering trial 1 anterior-posterior dose profile DTAs, measured
in the sagittal plane
For the A-P shifts, we see minimal average DTAs that are well within the
acceptable 3mm tolerance limits for each passive scattering trial.

3.4 Spot Scanning Phantom Dose Measurements
3.4.1

Absolute Dose Comparison
For an absolute dose comparison, the TLD doses as predicted in the treatment

planning system were compared to the measured dose from the TLD capsules in each
trial. The ratio of measured to calculated dose is also calculated in Table 3.6. Both
capsules were expected to receive 490 cGy.
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Trial 1

Trial 2

Trial 3

TLD
Location
Right
Anterior
Left
Posterior
Right
Anterior
Left
Posterior
Right
Anterior
Left
Posterior

Spot Scan
Calculated Dose [cGy] Measured Dose [cGy]
- TPS
- TLD

Meas./Calc. Dose

490

490.7

1.001

490

489.8

1.000

490

489.3

0.999

490

490.6

1.001

490

489.7

0.999

490
494.9
1.010
Table 3.6. Point dose comparisons between the treatment planning system and TLD
for spot scanning
The data demonstrate excellent agreement between the treatment planning system
and the TLD measurements for the spot scanning proton beam treatment plans, with a
maximum difference of only 1%. These numbers are well within the typical uncertainty
of TLD and within the criteria of acceptability. The agreement between measured and
calculated values is comparable to those found by Zhu et al. when verifying patient
specific treatment planning calculations with measured point doses (26).
The reproducibility, as with the passive scattering plan, was calculated by
computing the COV of the average TLD measurements for each location. The
reproducibility is summarized in Table 3.7.
Spot Scanning
Right
Left
TLD Location
Anterior
Posterior
Calculated Dose [cGy]
490
490
Measured Dose Avg. [cGy]
489.9
491.8
COV
0.15%
0.56%
Measured/Calculated Dose
1.000
1.004
Table 3.7. Average spot scanning dose over three trials
The COV for each TLD position was less than 0.6%, which is well under the 3%
reproducibility criterion. This indicates that the setup for the spot scanning trial
irradiations was reproducible, and could be recreated for the purpose of future audits.
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3.4.2

2D Dose Distribution Analysis
As with the passive scattering treatment plan, the two-dimensional dose

distribution was analyzed by comparing the dose clouds from the treatment planning
system with the dose profiles from the films in the phantom. Film and CT registrations
were all achieved with RMS < 1 mm, with the RMS Error ranging from 0.2553-0.7177
mm for film, and a 3D RMS of 0.68 for the CT images (the CT point registration was
used for all trials). The gamma analyses for the sagittal plane of trial 1 of the spot
scanning plan is shown below in and the complete 2D gamma analysis results for each
spot scanning trial are listed in Table 3.8.

a.
b.
Figure 3.9. Spot scanning trial 1 sagittal gamma analysis (a. 5%/3mm, b. 5%/5mm)
Spot Scanning Doses
2D Gamma Percentage of Pixels Passing
5%, 3mm 5%, 5mm
88.12
98.97
Trial 1 Coronal
Sagittal
97.32
99.91
84.86
98.56
Trial 2 Coronal
Sagittal
98.79
99.74
80.59
93.56
Trial 3 Coronal
Sagittal
92.89
99.74
Table 3.8. 2D gamma analysis pass rates for the spot scanning irradiations
The film passed well with the 5%/5mm criteria. The stricter 5%/3mm criteria
were not met as well, with the coronal planes showing poorer pixel pass rates for every
trial. However, the combined average pass rates for each trial all exceed the 85% pixel
pass rate criteria set forth by the RPC, as shown in Table 3.9.
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Spot Scanning
2D Gamma Pass Rate – Per Trial
5%, 3mm 5%, 5mm
Trial 1
92.7
99.4
Trial 2
91.8
99.2
Trial 3
86.7
96.7
Table 3.9. 2D gamma pass rates averaged over each trial irradiation
When reviewing the average gamma pass rates for different planes, all show good
agreement except the coronal plane for the 5%/3mm criteria, where the pixel pass rate
was just under the desired 85%, as delineated in Table 3.10. However, the coronal films
had good agreement (97%) under 5%/5mm criteria. This suggests that pixel shift is
present between the planned dose distribution and the physical delivery in the coronal
plane.
Spot Scanning
2D Gamma Pass Rate
5%, 3mm
5%, 5mm
Coronal
84.5
97.0
Sagittal
96.3
99.8
Sum
90.4
98.4
Table 3.10. 2D gamma pass rates averaged by film plane
3.4.3

Distance to Agreement
The treatment planning dose profiles were measured against the film dose profiles

to obtain distance to agreement values. As with the passive scattering measurements, the
DTAs were determined in the dose falloff regions over varying ranges depending on the
doses available on the film. These ranges were kept consistent for all trials, but varied by
plane. The average spot scanning DTAs are shown in Table 3.11.

Left
Right
Inferior
Superior
Posterior
Anterior

Spot Scanning
Distance to Agreement Shifts
Average DTA [mm] Std Deviation [mm]
0.1
0.8
3.4
0.5
-1.8
0.9
2.2
1.7
-1.2
0.4
0.0
0.5
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Table 3.11. Distance to agreement measurements between dose distributions from
treatment plans and from film measured for spot scanning proton beams
As with the passive scattering irradiations, we see the greatest disagreement
between the treatment planning system prediction and measured film dose profiles in the
coronal plane in the L-R direction. The distance to agreement measurements were
calculated between the 80% and 50% dose points for both the left and right sides for all
trials. This dose profile is shown in Figure 3.10.
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Figure 3.10. Spot scanning trial 1 right-left dose profile DTAs, measured in the
coronal plane
The left side of the dose profile shows good agreement between the TPS and film,
but the right side has much greater average displacement, with film doses not reaching as
far as the treatment planning system predicts. This right side displacement is greater than
the 3mm we desire for the stricter criteria, as highlighted in the circled areas of gamma
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analysis failure in Figure 3.11. However when we look at these same regions of interest
within the looser 5mm standards, the gamma analysis shows better agreement.

a.

b.
Figure 3.11. Spot scanning trial 1 coronal gamma analysis with areas of
disagreement highlighted (a. 5%/3mm, b. 5%/5mm)
The disagreement highlighted in Figure 3.11is present in all of the right-left

gamma analyses for each of the three spot scanning trials. The disagreement in the lower
left corner of the film is most concerning, as this indicates dose to a region outside of the
target. We suspect a small shift is responsible for this disagreement (and thus the
disagreement is not seen on the loser 5%/5mm criteria). However the DTA calculations
do not reflect this disagreement in the right-left profile due to the positioning of the DTA
profile across the center of the piece of film. Taking this into account, it might be
advantageous to run a profile and DTA measurements across a more inferior portion of
the film plane. This would give us a more quantifiable shift calculation for the dose to the
region of normal tissue.
As with the passive scattering trials, the S-I DTAs suggest the film doses were
delivered over a narrower extent than the treatment planning dose profiles, as shown
below in Figure 3.12. The DTAs were measured from the 80% to 30% dose points on the
inferior side, and the 80% to 50% dose points on the superior side. While the inferior
DTA is consistently greater than the superior side, both shifts are within the 3 mm
criteria.
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Figure 3.12. Spot scanning trial 1 S-I dose profile DTAs, measured in the coronal
plane
The anterior-posterior dose profiles showed minimal shift on both the anterior and
posterior sides. The DTAs were calculated for the dose point ranges between 80% and
60% on the posterior side, and between 80% and 50% on the anterior side. The Trial 1
profile comparisons are shown in Figure 3.13. The displacement on each side is less than
1.3 mm, well within our 3 mm criteria.
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Figure 3.13. Spot scanning trial 1 A-P dose profile DTAs, as measured in the sagittal
plane

3.5 Passive Scattering & Spot Scanning Results Comparison
The passive scattering and spot scanning irradiation results are comparable under
most criteria, but there are a few areas of distinction worth highlighting. First, though
both systems passed the absolute point dose criteria, the passive scattering system
showed much greater disagreement (1.8 – 3.5%) than the spot scanning system (<1%).
However, in a previous study conducted at the PTC-H by Zullo et al., TLD-100 was
found to predict dose within ±5% of predicted dose for passively scattered beams, which
agrees well with our results (39).
Another area of difference between the passive scattering and spot scanning
systems was the gamma analysis in each film plane, as shown in Table 3.12. While the
passive scattering system showed good agreement in the coronal plane, the spot scanning
system showed poorer agreement in this plane. As discussed above, the lower pass rate of
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the spot scanning system in the coronal plane was likely caused by a right-left shift of the
phantom or dose delivery, as the spot scanning coronal gamma pass rate increases
significantly for the 5%/5mm criteria. However there was not a larger right-left DTA
shift observed in the spot scanning system over the passive scattering system. But as
mentioned in Section 3.4.3, the DTA measurement is only made over a profile capturing
a singular slice of the film plane, and as such may misrepresent the DTA over the entire
film plane.
2D Gamma Percentage of Pixels Passing 5%, 3mm Criteria
Passive Scattering
Spot Scanning
91.50
88.12
Coronal
Trial 1
Sagittal
93.90
97.32
91.28
84.86
Coronal
Trial 2
Sagittal
91.85
98.79
88.00
80.59
Coronal
Trial 3
Sagittal
94.86
92.89
Table 3.12. 2D gamma analysis pixel pass rates for 5%/3mm criteria
Lastly, continuing the discussion of distance to agreement measurements, the
passive scattering and spot scanning systems demonstrated comparable DTAs in every
direction except the superior direction; the passive scattering irradiations showed a
superior DTA of 0.6 mm, while the spot scanning irradiations had an average DTA of 2.2
mm. These shifts are both within the limits set, but there may have been a greater error in
positioning of the phantom during the spot scanning irradiations that contributed to a
larger dose disagreement in the superior direction. This likely also contributed to the
lower 2D gamma analysis pass rates of the spot scanning films in the coronal plane.

56

4 Conclusions
4.1 Meeting Specific Aims
This project was designed to create and test a proton therapy head phantom to be
used for auditing proton facilities participating in clinical trials. The hypothesis was to
see if the treatment procedure could produce measured doses that agreed with calculated
doses within 5%/3mm with a reproducibility of 3%.
The first specific aim, to select a head phantom design and find appropriate
materials for the phantom construction, was achieved. The design of the phantom allows
for easy simulation, especially with the presence of a human skull, which improves
image-guided setup. The tissue equivalent phantom materials tested and used – the
Alderson material, nylon, high density polyethylene, and acrylic – were all found to lie
close to the calibration curve for stopping power and Hounsfield units used in the PTC-H
Eclipse treatment planning system. This allowed the phantom to best simulate human
anatomy for the target site.
As the phantom materials were developed with the treatment process in mind, we
were able to successfully simulate the phantom using MR and CT, with the appropriate
phantom materials showing up well on the imaging modalities. The MR simulation was
time consuming, which was not preferable, but the image quality was well suited for
target delineation when the image set was fused with the CT images. Treatment plans for
both the passive scattering and spot scanning systems were created that both met the
modified dose constraints of the clinical trial under consideration and met the department
standards at the PTC-H, as verified by a staff physician. The phantom was irradiated
without problem on both the passive scattering and spot scanning proton beams at the
PTC-H, completing the work described in specific aim two.
Specific aim three was achieved when the point doses and dose distributions for
each trial of each irradiation were measured by TLD and film, respectively. When
performing the film calibration, it was discussed whether or not to include the 7.5 Gy
data points when calculating the optical density relation. This would have made the 5.5
Gy data point the last in the series. Since the high treatment doses expected were around
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5.4 Gy, and some “hot” spots were anticipated, it was decided that including the 7.5 Gy
data point was appropriate to get a better polynomial fit over the range of doses.
Research work for specific aim four was completed by comparing the film and
TLD results from the trial irradiations to the corresponding quantities calculated by the
treatment planning system. The deviations and precision of the point doses and 2D dose
calculations were measured and analyzed, and showed acceptable results according to our
pass rate criteria set for the phantom, with an average of 91.9% of passive scattering
pixels and 90.4% of spot scanning pixels passing 5%/3mm gamma analysis criteria, with
a reproducibility within 0.8% for the passive scattering system and within 0.6% for the
spot scanning system.
There were some limitations in the accuracy of our data associated with specific
aim four. When performing the gamma analyses for the dose distribution comparisons,
the passive scattering analysis did not utilize the same CT registration for all trials, due to
difficulties with the MATLAB software. This produced a range of 3D RMS errors for the
CT registration, which may have contributed to overall uncertainty in the gamma
analysis. If the project were to be repeated, the same CT registration would be used for all
irradiation trials.
The greatest area of concern with the distance to agreement shifts observed
between film and treatment planning profiles is the large shift observed on the right side
of the coronal films. It is unexpected that the right side shift should disagree so much
with the left side, and for that reason it needs to be reinvestigated more carefully. One
possible explanation of this disagreement is a rotation in the setup of the phantom head
before irradiation. It is possible that one of the leveling screws was bumped from the
original simulation position, which could have caused a minimal shift on one side of the
profile and a greater disagreement on the other side. If this is the case, simply adjusting
the resistance of the leveling screws, or creating a way of marking their level, could help
prevent future misalignment.
The distance to agreement measurements in the S-I and A-P directions were
minimal and agree well with the predictions from the treatment planning system, within
our 3 mm criterion.
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It seems that the passive scattering plans demonstrate strong overall alignment, with the
pixel pass rate not changing much between the 5%/3mm and 5%/5mm criteria, while the
spot scanning treatment plans seem to show a shift disagreement, but better overall dose
agreement between the treatment plan and dosimetric measurements. Perhaps these
results can help the proton community better analyze the uncertainties associated with
phantom measurements for both the passive scattering and spot scanning treatment
delivery systems.
The hypothesis of this project was that an anthropomorphic head phantom could be
developed to evaluate proton therapy patient simulation, treatment planning, and
treatment delivery to assure agreement between the measured dose and calculated dose
within ±5%/3mm with a reproducibility of ±3%. With over 90% 5%/3mm agreement for
both the passive scattering and spot scanning systems, and a reproducibility within 0.8%
for both systems, the experiments support the hypothesis that a head phantom suitable for
the evaluation of proton therapy can be created and commissioned to meet the agreement
and reproducibility standards.
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4.2 Clinical Significance
As previously discussed, there is a need to verify the proton therapy treatment
procedures for institutions participating in relevant clinical trials. With the phantom
measurements of dose distribution showing good agreement with those from the
treatment planning system, it can be used as a benchmark for facilities wishing to enter
proton therapy clinical trials involving the treatment of brain tumors. The RPC would
require that a proton therapy facility successfully complete the phantom irradiation audit
procedure either before they treated patients on the clinical trial protocol or before a
certain number of patients was treated. This standard of credentialing would help ensure
that all proton therapy institutions are performing to the same high standards in order to
ensure excellent patient care and clinically viable research trial results. This credentialing
process not only benefits the patients participating in clinical trials, but also any patient
that is subsequently treated on a proton therapy machine that has undergone the RPC
phantom quality assurance process.

4.3 Future Directions
Based on the results of the study, it seems appropriate to begin use of the head
phantom for the auditing of proton therapy treatment facilities. Initially, the phantom may
be used on RPC site visits to participating institutions. If the phantom proves to work
well for the site visits, the RPC should be able to incorporate it into the mailable phantom
program. This will take some adjustment of current phantom irradiation instructions and
procedures.
To further improve upon the phantom design, it might be desirable to add critical
structures to the phantom (or a new one like it) to increase the difficulty of the phantom
irradiation, as well as collect data on the proton centers’ ability to avoid dosing such
structures. Another future direction that was discussed throughout the course of the
project was adapting the phantom to include a typical Head & Neck target, such as an
oropharyngeal or nasopharyngeal tumor volume. The phantom, with its anatomical
mimicry of nasal and oral passageways, would be well suited for a realistic experiment of
this type. It may prove difficult to properly model human air passages, as a common
clinical problem with treatment planning and delivery in such areas is the changing
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volume of mucus within these cavities. This could be modeled in the phantom by
introducing gel or a gel-filled balloon into the phantom airways, and may be a good way
of looking at the discrepancy between the planned v. delivered doses when mucus
volume changes. With the addition of any of these modifications, the phantom could be
improved from its original design to adapt to the changing needs of proton therapy audits.
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5 Appendix
5.1 Gamma Analysis
5.1.1

Passive Scattering Plan

a. 5%/3mm: 91.50% pass
b. 5%/5mm: 98.74% pass
Figure 5.1. Passive Scattering Trial 1 Coronal Gamma Analyses

a. 5%/3mm: 93.90% pass
b. 5%/5mm: 94.69% pass
Figure 5.2. Passive Scattering Trial 1 Sagittal Gamma Analyses
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a. 5%/3mm: 91.28% pass
b. 5%/5mm: 97.63% pass
Figure 5.3. Passive Scattering Trial 2 Coronal Gamma Analyses

a. 5%/3mm: 91.85% pass
b. 5%/5mm: 98.62% pass
Figure 5.4. Passive Scattering Trial 2 Sagittal Gamma Analyses
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a. 5%/3mm: 88.0% pass
b. 5%/5mm: 96.26% pass
Figure 5.5. Passive Scattering Trial 3 Coronal Gamma Analyses

a. 5%/3mm: 94.86% pass
b. 5%/5mm: 98.61% pass
Figure 5.6. Passive Scattering Trial 3 Sagittal Gamma Analyses
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5.1.2

Spot Scanning Plan

a. 5%/3mm: 88.12% pass
b. 5%/5mm: 98.97% pass
Figure 5.7. Spot Scanning Trial 1 Coronal Gamma Analyses

a. 5%/3mm: 97.32% pass
b. 5%/5mm: 99.91% pass
Figure 5.8. Spot Scanning Trial 1 Sagittal Gamma Analyses
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a. 5%/3mm: 84.86% pass
b. 5%/5mm: 98.56% pass
Figure 5.9. Spot Scanning Trial 2 Coronal Gamma Analyses

a. 5%/3mm: 98.79% pass
b. 5%/5mm: 99.74% pass
Figure 5.10. Spot Scanning Trial 2 Sagittal Gamma Analyses
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a. 5%/3mm: 80.59% pass
b. 5%/5mm: 93.56% pass
Figure 5.11. Spot Scanning Trial 3 Coronal Gamma Analyses

a. 5%/3mm: 92.89% pass
b. 5%/5mm: 99.74% pass
Figure 5.12. Spot Scanning Trial 3 Sagittal Gamma Analyses
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5.2 Dose Profile Comparisons
5.2.1

Passive Scattering Plan

5.2.1.1 Trial 1
See Section 3.3.3 for trial 1 results.
5.2.1.2 Trial 2
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Figure 5.13. Passive scattering trial 2 R-L dose profile DTAs, measured in the
coronal plane
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Superior-Inferior Profile - Coronal Plane
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Figure 5.14. Passive scattering trial 2 S-I dose profile DTAs, measured in the
coronal plane
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6

Posterior

Anterior

5

Dose [Gy]

-1.5 mm
-1.0 mm
-0.1 mm

1.3 mm

4

0.9 mm

3
2
1

Average DTA:
-0.9 mm
-4

-3

0.4 mm
Average DTA:
0.9 mm

0
-2

-1

0

1

2

3

Transverse Position [cm]
TPS
Film Dose

Figure 5.15. Passive scattering trial 2 A-P dose profile DTAs, measured in the
sagittal plane
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4

5.2.1.3 Trial 3

Right-Left Profile - Coronal Plane
6

Patient
Left

Patient
Right

5

-0.1 mm

3.6 mm

Dose [Gy]

4

3.5 mm

0.5 mm
3

0.9 mm

2
1

Average DTA:
0.2 mm
-4

-3

3.4 mm

Average DTA:
3.5 mm

0
-2

-1

0

1

2

3

4

Lateral Position [cm]
TPS
Film Dose

Figure 5.16. Passive scattering trial 3 L-R dose profile DTAs, measured in the
coronal plane
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Figure 5.17. Passive scattering trial 3 S-I dose profile DTAs, measured in the
coronal plane
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Anterior-Posterior Profile - Sagittal Plane
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Figure 5.18. Passive scattering trial 3 A-P dose profile DTAs, measured in the
sagittal plane
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4

5.2.2

Spot Scanning Plan

5.2.2.1 Trial 1
See Section 3.4.3 for trial 1 results.
5.2.2.2 Trial 2
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Figure 5.19. Spot scanning trial 2 R-L dose profile DTAs, measured in the coronal
plane
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Figure 5.20. Spot scanning trial 2 S-I dose profile DTAs, measured in the coronal
plane
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Figure 5.21. Spot scanning trial 2 A-P dose profile DTAs, measured in the sagittal
plane
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5.2.2.3 Trial 3
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Figure 5.22. Spot scanning trial 3 R-L dose profile DTAs, measured in the coronal
plane
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Figure 5.23. Spot scanning trial 3 S-I dose profile DTAs, measured in the coronal
plane
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Figure 5.24. Spot scanning trial 3 A-P dose profile DTAs, measured in the sagittal
plane

75

6 References
1.

ASTRO. 2010. Statistics: About Radiation Therapy. Fairfax, VA.

2.

RPC. 2010. Radiological Physics Center - RPC Website. R. P. Center, editor,
Houston, TX.

3.

NAPT. 2011. Proton Therapy - The National Association for Proton Therapy
(NAPT) Proton Beam Therapy, Protons and Prostate Cancer. National
Association for Proton Therapy.

4.

QARC. 2010. Quality Assurance Review Center. Providence, RI.

5.

Grant, R. 2010. Implementation of an Anthropomorphic Pelvis Phantom for the
Evaluation of Proton Therapy Treatment Procedures. In Radiation Physics.
University of Texas Health Science Center at Houston, Houston, TX. 103.

6.

Blatnica, A. 2011. Modification and Implementation of the RPC Heterogeneous
Thorax Phantom for Verification of Proton Therapy Treatment Procedures. In
Graduate School of Biomedical Sciences - Medical Physics. University of TX,
Houston.

7.

Bogdanich, W. 2010. As Technology Surges, Radiation Safeguards Lag. In The
New York Times. The New York Times, New York, NY.

8.

Bogdanich, W., and K. Rebelo. 2010. They Check the Medical Equipment, but
Who Is Checking Up on Them? In The New York Times. The New York Times,
New York, NY.

9.

ICRU. 2007. 9 QUALITY ASSURANCE. In JOURNAL OF THE ICRU. 135139.

10.

IAEA, P. Andreo, D. T. Burns, K. Hohlfeld, M. S. Huq, T. Kanai, F. Laitano, V.
G. Smyth, and S. Vynckier. 2000. Code of Practice for Proton Beams. In
Absorbed Dose Determination in External Beam Radiotherapy: An International
Code of Practice for Dosimetry Based on Standards of Absorbed Dose to Water.
IAEA, Vienna. 181.

11.

NCI. 2007. Guidelines for the Use of Proton Radiation Therapy in National
Cancer Institute Sponsored Cooperative Group Clinical Trials. National Cancer
Institute.
76

12.

RTOG, L. C. Rogers, M. A. Vogelbaum, A. Perry, B. Dean, A. P. Dicker, K.
Camphausen, L. Ashby, C. I. Tsien, M. Wang, J. Galvin, H.-M. Lu, and H. A.
Shih. 2011. RTOG 0539 - Phase II Trial of Observation for Low-Risk
Meningiomas and of Radiotherapy for Intermediate- and High-Risk
Meningiomas.

13.

Smith, A. R. 2009. Vision 20/20: proton therapy. Med Phys 36:556-568.

14.

Wilson, R. R. 1946. Radiological use of fast protons. Radiology 47:487-491.

15.

ICRU. 2007. 3 BEAM DELIVERY AND PROPERTIES. In JOURNAL OF THE
ICRU. 29-48.

16.

ICRU. 1993. 2 ELECTRONIC (COLLISION) STOPPING POWERS FROM
BETHE'S THEORY. JOURNAL OF THE ICRU:12.

17.

Joiner, M., and A. van der Kogel. 2009. Basic clinical radiobiology. Hodder
Arnold ;, London.

18.

ICRU. 2007. 1 INTRODUCTION. In JOURNAL OF THE ICRU. 11-20.

19.

Paganetti, H., A. Niemierko, M. Ancukiewicz, L. E. Gerweck, M. Goitein, J. S.
Loeffler, and H. D. Suit. 2002. Relative biological effectiveness (RBE) values for
proton beam therapy. International Journal of Radiation
Oncology*Biology*Physics 53:407-421.

20.

Weber, D. C., A. J. Lomax, H. Peter Rutz, O. Stadelmann, E. Egger, B.
Timmermann, E. S. Pedroni, J. Verwey, R. Miralbell, G. Goitein, and G. The
Swiss Proton Users. 2004. Spot-scanning proton radiation therapy for recurrent,
residual or untreated intracranial meningiomas. Radiotherapy and Oncology
71:251-258.

21.

ICRU. 2007. 2 RADIATION BIOLOGY CONSIDERATIONS. In JOURNAL
OF THE ICRU. 21-28.

22.

Akagi, T., A. Higashi, H. Tsugami, H. Sakamoto, Y. Masuda, and Y. Hishikawa.
2003. Ridge filter design for proton therapy at Hyogo Ion Beam Medical Center.
Physics in Medicine and Biology 48.

23.

Smith, A., M. Gillin, M. Bues, X. R. Zhu, K. Suzuki, R. Mohan, S. Woo, A. Lee,
R. Komaki, J. Cox, K. Hiramoto, H. Akiyama, T. Ishida, T. Sasaki, and K.

77

Matsuda. 2009. The M. D. Anderson proton therapy system. Medical Physics
36:4068-4083.
24.

Gillin, M. T., N. Sahoo, M. Bues, G. Ciangaru, G. Sawakuchi, F. Poenisch, B.
Arjomandy, C. Martin, U. Titt, K. Suzuki, A. R. Smith, and X. R. Zhu. 2009.
Commissioning of the discrete spot scanning proton beam delivery system at the
University of Texas M.D. Anderson Cancer Center, Proton Therapy Center,
Houston. Medical Physics 37:154-163.

25.

ICRU. 2007. 4 DOSIMETRY. In JOURNAL OF THE ICRU. 49-81.

26.

Zhu, X. R., F. Poenisch, X. Song, J. L. Johnson, G. Ciangaru, M. B. Taylor, M.
Lii, C. Martin, B. Arjomandy, A. K. Lee, S. Choi, Q. n. Nguyen, M. T. Gillin, and
N. Sahoo. 2011. Patient-Specific Quality Assurance for Prostate Cancer Patients
Receiving Spot Scanning Proton Therapy Using Single-Field Uniform Dose.
International Journal of Radiation Oncology*Biology*Physics In Press, Corrected
Proof.

27.

Tew, J., N. McMahon, and T. Orgon-Stamper. 2009. Meningioma. Mayfield
Clinic, Cincinnati, OH.

28.

Castillo, G. C. 2010. Meningioma, Brain. WebMD LLC.

29.

BSF. 2010. Meningiomas - Primary Brain Tumors. Brain Science Foundation,
Inc., Wellesley, MA.

30.

Gudjonsson, O., E. Blomquist, G. Nyberg, L. Pellettieri, A. Montelius, E. Grusell,
C. Dahlgren, U. Isacsson, A. Lailja, and B. Glimelius. 1999. Stereotactic
irradiation of skull based meningiomas with high energy protons. Acta
Neurochirurgica 141:8.

31.

Molineu, A., D. S. Followill, P. A. Balter, W. F. Hanson, M. T. Gillin, M. S. Huq,
A. Eisbruch, and G. S. Ibbott. 2005. Design and implementation of an
anthropomorphic quality assurance phantom for intensity-modulated radiation
therapy for the Radiation Therapy Oncology Group. International Journal of
Radiation Oncology*Biology*Physics 63:577-583.

32.

Followill, D., D. R. Evans, C. Cherry, A. Molineu, G. Fisher, W. F. Hanson, and
G. S. Ibbott. 2007. Design, development, and implementation of the radiological

78

physics center's pelvis and thorax anthropomorphic quality assurance phantoms.
Medical Physics 34:6.
33.

Shrimpton, P. C., B. F. Wall, and E. S. Fisher. 1981. The tissue-equivalence of the
Alderson Rando anthropomorphic phantom for x-rays of diagnostic qualities.
Phys Med Biol 26:7.

34.

HAI. 2010. Advanced Markus Chamber Type 34045. Harpell Associates Inc.

35.

Moyers, M. F., M. Sardesai, S. Sun, and D. W. Miller. 2009. Ion stopping powers
and CT numbers. Medical Dosimetry In Press, Uncorrected Proof.

36.

Gottschalk, B. 2004. Passive Beam Spreading in Proton Radiation Therapy.
Harvard High Energy Physics Laboratory, Cambridge, MA. 144.

37.

Schaffner, B., and E. Pedroni. 1998. The precision of proton range calculations in
proton radiotherapy treatment planning: experimental verification of the relation
between CT-HU and proton stopping power. Phys Med Biol 43:1579-1592.

38.

Sabini, M. G., L. Raffael, M. Bucciolini, G. A. Cirrone, G. Cuttone, S. Lo Nigro,
S. Mazzocchi, V. Salamore, and L. M. Valastro. 2002. The use of
thermoluminescent detectors for measurement of proton dose distribution. Radiat
Prot Dosimetry 101:4.

39.

Zullo, J. R., R. J. Kudchadker, X. R. Zhu, N. Sahoo, and M. T. Gillin. 2010. LiF
TLD-100 as a Dosimeter in High Energy Proton Beam Therapy--Can It Yield
Accurate Results? Medical Dosimetry 35:63-66.

40.

Knoll, G. F. 2000. Radiation detection and measurement. Wiley, New York.

41.

Kirby, T. H., W. F. Hanson, R. J. Gastorf, C. H. Chu, and R. J. Shalek. 1986.
Mailable TLD system for photon and electron therapy beams. International
Journal of Radiation Oncology*Biology*Physics 12:261-265.

42.

Rosner, B. 2006. Fundamentals of Biostatistics. Thomson-Brooks/Cole, Belmont,
CA.

43.

Vatnitsky, S. M. 1997. Radiochromic film dosimetry for clinical proton beams.
Applied Radiation and Isotopes 48:643-651.

44.

ISP. 2009. Gafchromic EBT2 Self-developing Film for Radiotherapy Dosimetry.
International Specialty Products, Inc., New Jersey. 17.

79

45.

Soares, C. G. 2006. Radiochromic film dosimetry. Radiation Measurements
41:S100-S116.

46.

Zhao, L., and I. J. Das. Gafchromic EBT film dosimetry in proton beams. Phys
Med Biol 55:N291-301.

47.

Arjomandy, B., N. Sahoo, G. Ciangaru, R. Zhu, X. Song, and M. Gillin.
Verification of patient-specific dose distributions in proton therapy using a
commercial two-dimensional ion chamber array. Medical Physics 37:5831-5837.

48.

Kirby, D., S. Green, H. Palmans, R. Hugtenburg, C. Wojnecki, and D. Parker.
2010. LET dependence of GafChromic films and an ion chamber in low-energy
proton dosimetry. Phys Med Biol 55:417-433.

80

Vita
Paige Alexandra Summers was born in Portland, Oregon on March 4, 1987 to
Von and Susan Summers. After graduating Valedictorian of Woodrow Wilson High
School in Portland in 2005, Paige continued on to Santa Clara University. In 2009, she
received her SCU Bachelor of Science Degree in Physics, with minors in Mathematics
and Spanish. In August of 2009 she began her graduate studies at the University of Texas
– Houston Graduate School of Biomedical Science, where she is pursuing a Masters in
Medical Physics.

1

